Theravance Biopharma, Takeda deal

Theravance granted Takeda worldwide rights to develop and commercialize candidate TD-8954, a serotonin (5-HT4) receptor agonist in development for gastrointestinal motility disorders. Theravance will receive an upfront cash payment of $15 million and is eligible for up to $110 million in development, sales and launch milestones, plus double-digit royalties. ...